Key Points
- Director John Henneman III bought 5,000 shares on May 1 at an average price of $14.66 (total $73,300), raising his stake 10.03% to 54,871 shares; the purchase was disclosed in an SEC filing.
- Anika beat quarterly expectations with $0.27 EPS (vs. -$0.07 est.) and $29.61M revenue (vs. $28.14M), but still reports a negative net margin (-9.52%) and negative ROE (‑5.90%) and analysts forecast -$0.61 EPS for the current year.
- Analyst views are mixed—Barrington raised its target to $17 and the consensus target is $17 with an average "Hold" rating—while the stock has a market cap of about $193.7M and is roughly 91.53% institutionally owned.
Anika Therapeutics Inc. (NASDAQ:ANIK - Get Free Report) Director John Henneman III bought 5,000 shares of the business's stock in a transaction that occurred on Friday, May 1st. The stock was acquired at an average cost of $14.66 per share, with a total value of $73,300.00. Following the completion of the acquisition, the director owned 54,871 shares of the company's stock, valued at $804,408.86. This represents a 10.03% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Anika Therapeutics Stock Performance
Shares of ANIK opened at $14.55 on Tuesday. The stock has a market capitalization of $193.66 million, a PE ratio of -18.42 and a beta of 0.16. The company's fifty day moving average is $14.31 and its 200 day moving average is $11.32. Anika Therapeutics Inc. has a fifty-two week low of $7.87 and a fifty-two week high of $16.24.
Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $0.27 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.34. Anika Therapeutics had a negative net margin of 9.52% and a negative return on equity of 5.90%. The business had revenue of $29.61 million during the quarter, compared to analyst estimates of $28.14 million. As a group, research analysts forecast that Anika Therapeutics Inc. will post -0.61 earnings per share for the current year.
Analysts Set New Price Targets
Several research analysts recently commented on the company. Barrington Research lifted their price target on Anika Therapeutics from $16.00 to $17.00 and gave the stock an "outperform" rating in a research report on Friday, February 27th. Wall Street Zen lowered Anika Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $17.00.
View Our Latest Stock Analysis on ANIK
Institutional Trading of Anika Therapeutics
A number of institutional investors have recently modified their holdings of the company. CWM LLC boosted its stake in Anika Therapeutics by 526.6% in the third quarter. CWM LLC now owns 7,457 shares of the biotechnology company's stock valued at $70,000 after acquiring an additional 6,267 shares in the last quarter. Quarry LP acquired a new position in Anika Therapeutics during the 3rd quarter valued at about $71,000. Ieq Capital LLC purchased a new stake in Anika Therapeutics in the fourth quarter valued at about $97,000. Occudo Quantitative Strategies LP purchased a new stake in Anika Therapeutics in the third quarter valued at about $95,000. Finally, Williams & Novak LLC acquired a new stake in Anika Therapeutics in the third quarter worth about $102,000. 91.53% of the stock is currently owned by institutional investors.
About Anika Therapeutics
(
Get Free Report)
Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika's proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.
The company's core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
